Zeus Capital has advised the main shareholders of Brabant Pharma on its sale to Nasdaq-listed Zogenix, in a deal worth up to $130m.
Brabant’s assets include worldwide development and commercialisation rights to BrabafenTM, which is a low-dose fenfluramine drug. It is used for the treatment of Dravet syndrome, a rare and catastrophic form of intractable epilepsy that begins in infancy. Children with Dravet syndrome experience frequent, severe and potentially life-threatening seizures that typically start in the first year of life.
Zogenix, which is quoted on Nasdaq, is a pharmaceutical company developing and commercialising products for the treatment of pain-related and central nervous system disorders.
Dan Bate, Director, Corporate Finance at Zeus Capital, commented: “We are delighted to have been involved in this transaction which was described by Joseph Sullivan, M.D, director of the University of California at San Francisco Pediatric Epilepsy Center as being transformational for Zogenix. Alongside our legal advisory team at Eversheds Manchester led by Danny Hall and Nicola Brookes, we were able to provide the advice and support that enabled our clients to maximise value and to complete the disposal of Brabant quickly and efficiently.”
Commenting on Brabafenâ„¢, Joseph Sullivan, M.D. said: “Based on the available long-term clinical data, Brabafenâ„¢ has the potential to transform the quality of life for Dravet Syndrome patients by eliminating or reducing seizures. The prognosis for seizure control in these patients is poor and current treatment alternatives offer little benefit. However, if the current positive results are demonstrated in controlled Phase 3 clinical trials, Brabafenâ„¢ could be a breakthrough treatment for patients with this catastrophic epilepsy syndrome.”